(more work needed - who's in dc arm office of jensen ceo prodigee rene .). doznes of engineers who have been at nvidia for 25 years doing life's work ...
notes on contents of Jensen guide to ai collaborations with productive human brainpower- file by year/month with additions to those in above doc labeled XX ;eg xx 2007.1..Jensen Huang interview with Taiwan's Maurice Chang (helps explain how much AI20s depends on Taiwanese people https://www.youtube.com/watch?v=u-x7PdnvCyI
-references to 25X involve data sovereignty applications deploying 25 times energy more efficient supercompute ..xx 24.9.1 https://www.youtube.com/watch?v=doJDuLMnaWc jensen testimony to dc bipartisan committee - launch of 25x supercompute - ability to build one every 3 months with sovereign data regional partners national energy week
25.6.1 Macron (3rd leg king charles ai nov 2023 summit- modi to be 4th) Lecun Mistral Mensch- Macron invites top deep 10 french corporates eg schneider volia ... to design deep search llms and startup infrastructure with Mistral (meta fair llama 3 with Yann Lecun), edge ai (eg dell),- first time ever EU country supported youth ai startups/ XX25.6.2 jensen uk ai summit with PM Sharmer & 10 corporates; keynote-
typical q to grok june 2025- what intelligence uses and data sovereignty maps will be priritised by places with 25x supercomputers
REINTRODUCTION TO JENSEN HUANG VIEWING
His tips are often brutally honest; unconventional wisdom has its place in studying entrepreneurship- at least i feel so ,my dad made this argument in The Economist from 1976
2013.1 how nvidia started in 1993
XX25.6.2 https://www.youtube.com/watch?v=SsNS3Xm9ig4 london tech week ai summit jensen keynote included maps of euro countries nvidia open partners (bloomberg coverage hunag uk prime minister Starmer
25.5.1 update taiwan 25x supercompute partners inluding 8 deepest corporates of taiwan as deep ai nation since 1987 national startegy of changs ai foundry and foudational maps of sme value chains of ai japan-korea--taiwan-Guo , H Li - (coming grok assessment of main applications of taiwan 25x compute
xx25.4.1 https://www.c-span.org/person/jensen-huang/141815/jensen and leading global ai industry friends collect solutions for and with president trump
xx 25.4.2 stephen witt author of thinking machines reviews first 25 years of jensen's 21st C https://www.c-span.org/program/book-tv/after-words-with-stephen-wit... 1 minute of jensens time is worth a million $ approx- at same time deep family kids now grown up jensen kids 28.30 come from louis vuitton and cocktail bar taiwan before now at nvidila- see also 2010.1 family launch stanford's deep learning lab- hugely supportive engineering wife lori- noth enegineers at orgeon state (big gift) jargon check min 5.5what is a gpu? 14.30 what is supercomputer's operating language "platform" cuda (and how did this emerge from lifework inspirations inspirations like medical imaging, early material after big bang and weather forecasting ) 18 mins headhunt bill daly 2009 (science users of supercompute before ai) - what if i can help your science work be 1000 times faster (nvidia enters mamograms early 200s as well as coding pixels with steve jobs pixar) 44.00 what is omniverse - eg robot simulation dishwashing by breaking a million dishes in virtual world before. 48.30 pivoting whole cokpany on neural nets before even the ai expsrts understood!.. (2009 stnafird deep learning lab)
25.3.1 gtc 2025 keynote- often jensens main annual update in usa. on eoof big abbouncement is Netwon Robot lab as partnership between nvidia (deep mind hassabis and google) and diseny now owners of pixar. This brings full circle one of earliest pixel coding partnerships between nvidia and pixar then owned by steve jobs. Newton Lab is for robots to train on physics of touch
25.3.2 At GTC jensen shares the stage with quantum companies to clarify their visions
25.1.1 At Consumer Electronics Show Jensen focused on advancing AI across industries, particularly through physical AI (AI that perceives, reasons, and acts in the real world) and NVIDIA’s new products. The keynote emphasized gaming, robotics, autonomous vehicles (AVs), and personal AI computing, powered by NVIDIA’s Blackwell architecture and Cosmos platform (this platform - an open-source world foundation model (WFM) platform (on Github & Hugging Face) designed to train and deploy physical AI for robotics and AVs
24.11.1 In Tokyo Jensen Huang interviews Softbank Maya Son. Celebrates builinding one of world's first 25 time X supercomputes in Japan around Maya Son's frineds. Back before covid Maya Son owned Arm and valued Nvidia. Coviud firced sell off his most profiatbale investment ie both Arm and Nvida. But ceos on siftbank, nvidia, arm have mainatied same vision - supercomputes need best of arm's cpus as well as nvidia's gpus. (If it hadnt been for Biden Justice departments mono0oly decision, nvidia and arm would be one company - see XX 24.9.1 https://www.youtube.com/watch?v=g5llbNt7_Ik
24.11.2 At CS24 annual (annual summit for high performsamnce computing developers) Buck and Jensen announce cuPyNumeric - this simplifies connectiosn python science programmers need between up to 450 python libraies nvidia offers
24.3.2 jensen brings together the 7 who broke through with transgormer model attemtion is all you need
24.3.1 Digital Twins was one of the interesting foci of jensens gtu 2024 keynote. Increasingly if you are building a factory for soace with robots it makes sense to digitally architect this first. That way you can uoyodate or replicate design of human and robot interaction. Notably Jensen and Taiwan companies value digital twins in case they are asked to move supply chains etc. (taiwan has over 40 years of being world class leader at advanced manufacturing dssign - clarifying exactly how to move designs with hundreds of parts has become too detailed a digital infrastructure game not to use AI.
24.3.3 GTc24 sees updates to Jensen's t=vision to 3 core models in one needed for erath 2.0 not just to be best weather forecast model but to plug and plau various climate chamge games. Jensen has announced with Taiwan the intention to make Taiwan world chlass epicentre of earth 2.0 modeling- Taiwan's national investment arm and data from IBM's weather company are early partners. Both Taiwan and Jaoan currently have to import most of their energy needs- suggesting they have win-win needs to understand future of energy
xx24.11.1 Indonesia AI Day https://www.youtube.com/watch?v=w64JT0HwqHI with Jensen Huang and Accenture's Julie Sweet https://indonesiaaiday.com/#section-speakers - see also numbers of accenture staff trained in AI
chris macrae
Kenichiro Watanabe, Director, National Healthcare Policy Secretariat, Cabinet Office
Rami Suzuki, Representative Director CEO, ARC Therapies Inc.
Shinichiro Fuse, TPG Life Sciences Innovations / Partner and Managing Director
Dan Kemp, CEO, Shinobi Therapeutics, Inc.
Mikkel Skovborg, Senior Vice President, Innovation, Novo Nordisk Foundation,
<Moderator>
Akihiko Soyama, CEO, Life Science Innovation Network Japan / Specially Appointed Professor, Tohoku University
10:50~11:00Break
11:00~11:50Special Session 1 Supported by Novartis Pharma KK
John Paul Pullicino, President and Representative Director, Novartis Pharma KK
Fumiaki Ikeno, Researcher, Stanford University
Kazumasa Oguro, Professor, Faculty of Economics, Hosei University
Masato Iwasaki, Senior Executive Fellow, IGPI Group, Inc.
<Moderator>
Yasuko Shoji, Manager, Research Unit / Medical & Healthcare Institute, Nikkei BP Intelligence Group, Nikkei Business Publications, Inc.
11:50~13:30Panel Session 2
Tadayoshi Mizutani,Director, Policy Planning Division for Pharmaceutical Industry Promotion and Medical Information Management, Health Policy Bureau, Ministry of Health, Labor and Welfare
Masaaki Miyakawa, Executive Board Member, Japan Medical Association
Hitoshi Kuboniwa, Japan Bioindustry Association,Chairman Steering Committee
Yukiko Nishimura, NPO ASrid, President
Yasuhiro Fujiwara, Chief Executive, Pharmaceuticals and Medical Devices Agency
Yuji Kashitani, Executive Director, Global Regulatory Policy & Innovation Japan, Takeda Development Center Japan
Masanobu Saito, Corporate Officer, Head of Value & Access, Japan, Novartis Pharma KK
Masahisa Jinushi, Executive Direcotr, Head of Medical Affairs, Gilead Sciences KK
<Moderator>
Shintaro Sengoku, Professor, School of Environment and Society, Institute of Science Tokyo
13:30~13:40Break
13:40~15:00Panel Session 3
Hirokazu Shimoda, Director, Bio-Industry Division, Commerce and Service Industry Policy Group, Ministry of Economy, Trade and Industry
Yoshiki Sawa, President,Organization of Future Medicine
Toshio Fujimoto, Chief Executive Officer, iPark Institute Co., Ltd.
Yusaku Katada, Restore Vision Inc. CEO
Morten Sogaard, Head, Innovation Lab, Astellas Pharma
Hiroo Igarashi, President & Representative Director, Pfizer Japan Inc.
<Moderator>
Masamitsu Harata, Chairman, CEO and Founder at Human Life CORD Japan Inc.
15:00~15:50Special Session 2 Supported by Novo Nordisk Pharma Ltd.
Koutaro Yokote, President, Japan Society for the Study of Obesity/ President, Chiba University
Ataru Igarashi, Associate Professor, Dept. of Public Health and Health Policy, Graduate School of Pharmaceutical Sciences, The University of Tokyo
15:50~16:00Special Speech 1
16:00~16:50Special Session 3 Supported by Gilead Sciences, Inc.
Wataru Sugiura, Director General, Center for Clinical Science, Japan Institute for Health Security
Hiroto Araki, Director, Infectious Diseases Control Division, Ministry of Health, Labor and Welfare
Toshio Fujimoto, Chief Executive Officer, iPark Institute Co., Ltd.
Kennet Brysting, President and Representative Director of Gilead Sciences KK
Toshihiko Takeda, Senior Advisor, Boston Consulting Group
16:50~17:00Break
17:00~18:00NIKKEI Drug Discovery Startup Pitch
Finalist Presentation DAY1
Masamitsu Harata, Chairman, CEO and Founder at Human Life CORD Japan Inc.
Toshio Fujimoto, Chief Executive Officer, iPark Institute Co., Ltd.
Tsuyoshi Tsujimura, Investment Principal, Investment Department, Kyoto University Innovation Capital Co., Ltd.
Masakazu Komahashi, General Manager, Investment Department Ⅲ, SMBC VENTURE CAPITAL CO., LTD.
【Day2】 Wednesday, June 25
9:00~9:20Special Speech 2
9:20~10:40Panel Session 4
Kanae Kurata, Director, Life Sciences Division, Research Promotion Bureau, Ministry of Education, Culture, Sports, Science and Technology (MEXT)
Shin Kaneko, Professor, Center for iPS Cell and Research Application, Kyoto University
Professor, Faculty of Medicine, University of Tsukuba
Kiyohumi Kaneshiro, Chief Financial Officer, PeptiDream Inc.
Takeyuki Akiyama, Director, Japan Alliance for Lysosomal Disease Patient Organizations
Shinichiro Komoto, Eight Roads Ventures Japan・Partner
Hiroshi Miyake, Chief Executive Officer, Chordia Therapeutics
<Moderator>
Aya Kubota, Editor in Chief, Nikkei Biotechnology & Business, Nikkei Business Publications, Inc.
10:40~11:30Special Session 4 Supported by Japan Pharmaceutical Manufacturers Association (JPMA)
Jin Shiomura, Founder, Managing Director & CEO of Nobelpharma
Sumito Nishidate, Chairman of the GIST & Sarcoma Patients and Families Association “NPO GISTERS”
Kazuhiko Mori, Senior Managing Director of Japan Pharmaceutical Manufacturers Association
Masami Sakoi, Chief Medical and Global Health Officer of Ministry of Health, Labor and Welfare
<Moderator>
Asuka Miyabashira – President of Japan Pharmaceutical Manufacturers Association
11:30~11:40Break
11:40~12:10Special Speech 3
12:10~13:30Panel Session 5
Yasushi Okuno, Professor, Department of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University
Akira Izumi, CEO & Founder, RyuWell Co.,LTD
Hidenobu Ishizaki, Executive director, Center for Development of Advanced Cancer Therapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research (JFCR)
Hiroyoshi Toyoshiba, Director/ Chief Technology Officer
Hiroyuki Tsunoda, Deputy Head of Research Division, Chugai Pharmaceutical Co., Ltd.
<moderator>
Masanori Shindo, Deputy General Manager, Life Intelligence Consortium general incorporated association</moderator>
13:30~13:40Break
13:40~14:00Special Session 5 Supported by Johnson & Johnson Innovative Medicine
Sarah Brennan, Company Group Chairman, Global Commercial Strategy Organization, for Johnson & Johnson Innovative Medicine
14:00~15:30Panel Session 6
Shintaro Sengoku, Professor, School of Environment and Society, Institute of Science Tokyo
Asuka Miyabashira, President of Japan Pharmaceutical Manufacturers Association
Takahiko Iwaya, Chair of European Federation of Pharmaceutical Industries and Associations, Japan (EFPIA Japan)
Hans Klemm, Japan Representative, Pharmaceutical Research and Manufacturers of America (PhRMA)
Hitoshi Nakagama, Japan Agency for Medical Research and Development/President
Kazuto Yamada, President and CEO, Japan Tissue Engineering Co., Ltd.
<Moderator>
Kiyoshi Ando, Senior Staff Writer, Nikkei Inc.
15:30~15:40Break
15:40~16:40NIKKEI Drug Discovery Startup Pitch
Finalist Presentation DAY2
Masamitsu Harata, Chairman, CEO and Founder at Human Life CORD Japan Inc.
Toshio Fujimoto, Chief Executive Officer, iPark Institute Co., Ltd.
Tsuyoshi Tsujimura, Investment Principal, Investment Department, Kyoto University Innovation Capital Co., Ltd.
Masakazu Komahashi, General Manager, Investment Department Ⅲ, SMBC VENTURE CAPITAL CO., LTD.
Speaker
Fumio Kishida
Member of the House of Representatives
Hideki Murai
Member of the House of Representatives
Akihisa Shiozaki
Member of the House of Representatives
Kazuto Ihara
Vice-Minister of Health, Labor and Welfare
Kenichiro Watanabe
Director, National Healthcare Policy Secretariat, Cabinet Office
Rami Suzuki
Representative Director CEO, ARC Therapies Inc.
Shinichiro Fuse
TPG Life Sciences Innovations
Partner and Managing Director
Dan Kemp
CEO, Shinobi Therapeutics, Inc.
Mikkel Skovborg
Senior Vice President, Innovation, Novo Nordisk Foundation,
Akihiko Soyama
CEO, Life Science Innovation Network Japan / Specially Appointed Professor, Tohoku University
John Paul Pullicino
President and Representative Director, Novartis Pharma KK
Fumiaki Ikeno
Researcher, Stanford University
Kazumasa Oguro
Professor, Faculty of Economics, Hosei University
Masato Iwasaki
Senior Executive Fellow, IGPI Group, Inc.
Yasuko Shoji
Manager, Research Unit
Medical & Healthcare Institute, Nikkei BP Intelligence Group, Nikkei Business Publications, Inc.
Tadayoshi Mizutani
Director, Policy Planning Division for Pharmaceutical Industry Promotion and Medical Information Management, Health Policy Bureau, Ministry of Health, Labor and Welfare
Masaaki Miyakawa
Executive Board Member, Japan Medical Association
Hitoshi Kuboniwa
Japan Bioindustry Association,Chairman Steering Committee
Yukiko Nishimura
NPO ASrid, President
Yasuhiro Fujiwara
Chief Executive, Pharmaceuticals and Medical Devices Agency
Yuji Kashitani
Executive Director, Global Regulatory Policy & Innovation Japan, Takeda Development Center Japan
Masanobu Saito
Corporate Officer, Head of Value & Access, Japan, Novartis Pharma KK
Masahisa Jinushi
Executive Director, Head of Medical Affairs, Gilead Sciences KK
Shintaro Sengoku
Professor, School of Environment and Society, Institute of Science Tokyo
Hirokazu Shimoda
Director, Bio-Industry Division, Commerce and Service Industry Policy Group, Ministry of Economy, Trade and Industry
Yoshiki Sawa
President,Organization of Future Medicine
Toshio Fujimoto
Chief Executive Officer, iPark Institute Co., Ltd.
Yusaku Katada
CEO, Restore Vision Inc.
Morten Sogaard
Head, Innovation Lab, Astellas Pharma
Hiroo Igarashi
President & Representative Director, Pfizer Japan Inc.
Masamitsu Harata
Chairman, CEO and Founder at Human Life CORD Japan Inc.
Kotaro Yokote
President, Japan Society for the Study of Obesity/ President, Chiba University
Ataru Igarashi
Associate Professor, Dept. of Public Health and Health Policy, Graduate School of Pharmaceutical Sciences, The University of Tokyo
Gaku Hashimoto
Professor, Faculty of Health and Welfare Services Administration, Kawasaki University of Medical Welfare (Former Member of the House of Representatives)
Wataru Sugiura
Director General, Center for Clinical Science, Japan Institute for Health Security
Hiroto Araki
Director, Infectious Diseases Control Division, Ministry of Health, Labor and Welfare
Kennet Brysting
President and Representative Director of Gilead Sciences KK
Toshihiko Takeda
Senior Advisor, Boston Consulting Group
Kanae Kurata
Director, Life Sciences Division, Research Promotion Bureau, Ministry of Education, Culture, Sports, Science and Technology (MEXT)
Shin Kaneko
Professor, Center for iPS Cell and Research Application, Kyoto University
Kaneshiro Kiyohumi
Chief Financial Officer, PeptiDream Inc.
Takeyuki Akiyama
Director, Japan Alliance for Lysosomal Disease Patient Organizations
Shinichiro Komoto
Eight Roads Ventures Japan・Partner
Hiroshi Miyake
Chief Executive Officer, Chordia Therapeutics
Aya Kubota
Editor in Chief, Nikkei Biotechnology & Business, Nikkei Business Publications, Inc.
Jin Shiomura
Founder, Managing Director & CEO of Nobelpharma
Sumito Nishidate
Chairman of the GIST & Sarcoma Patients and Families Association "NPO GISTERS"
Kazuhiko Mori
Senior Managing Director of Japan Pharmaceutical Manufacturers Association
Masami Sakoi
Chief Medical and Global Health Officer of Ministry of Health, Labor and Welfaresuka Miyabashira
President of Japan Pharmaceutical Manufacturers Association
Yasushi Okuno
Professor, Department of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University
Akira Izumi
CEO & Founder, RyuWell Co.,LTD
Hidenobu Ishizaki
Executive director, Center for Development of Advanced Cancer Therapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research (JFCR)
Hiroyoshi Toyoshiba
Director/ Chief Technology Officer
Hiroyuki Tsunoda
Deputy Head of Research Division, Chugai Pharmaceutical Co., Ltd.
Masanori Shindo
Deputy General Manager, Life Intelligence Consortium general incorporated association
Sarah Brennan
Company Group Chairman, Global Commercial Strategy Organization, for Johnson & Johnson Innovative Medicine
Takahiko Iwaya
Chair of European Federation of Pharmaceutical Industries and Associations, Japan (EFPIA Japan)
Hans Klemm
Japan Representative, Pharmaceutical Research and Manufacturers of America (PhRMA)
Hitoshi Nakagama
Japan Agency for Medical Research and Development/President
Kazuto Yamada
President and CEO, Japan Tissue Engineering Co., Ltd.
Kiyoshi Ando
Senior Staff Writer, Nikkei Inc.
Jun 24
chris macrae
Chartering is Q&A format we first publiished nearly 30 years ago - we were designing a process needed by organsiations aiming to serve f y64 352e a purpose that would be uniquely missed if they did not exist
Today, it feels as if intelligence could make the whole world better or worse. Which handful of intelligence designers do you most need to be influenced by. Please note in chartering we aim to avoid listing 2 people with very similar impacts. If you think we have missed someone out with an essential impact please tell us chris.macrae@yahoo.co.uk
AI Corporate Wizards 1 Jensen Huang -over 30 years now jensen and coworkers have redesigned computing to be a million + times more efficient for deep learning (and multidimensional) analysis which 21st C breakthroughs in AI depend on. WE can catalogue50 deepest partners of nvidia in different ways- countries: data sovereigntly; digital platforms eg self-drving cars in one of about 10 platforms that most majors connect through nvidia; supplying differentiated models as eg us 6 major digital comp[anoies (meta apple microsoft amazon google ,,,) become digital ai companies; full stack partnership eg from dell supplying devices at the edge to various digital twin services; links to ecosystems supporting 2000 startups in 100 countries; deep data partnerships eg with snowflake for clients of ai data warehousibg to service plus to safes force
There are 2 particula engineering circles which huang appears to be in middle of. 1 building 25X more energy efficient supercomputers. Which will be first 10 countries with these and what will each supercomputer specialise in. Ai foundriies - ed desiging ai for clients. Most of the world’s best engineers for doing this are in Taiwan. Whilst digital twinning will likely show what skillsare needed if a franchise is to move its supply cains to another hemisphere o0f the world, 50 years of advanced manufacturing skills (eg demin quaslity), accelerating value leaps every few months) involes webs of hundered of just in time suppliers. Its not obvious how many engineers beyomd jensen have all the truts relationships needed to do this.
AI Corperate Wizard 2 Demis was effectively the first to map pattern ai relevant to most of natural science challenges Einstein first -published E=mcsquared in 1905.With neumann einstein turing dyting suddenly in mod 1950s its almsot as if most of their wos forgotten untl hassabis rediscovered this early in 21st c. Back in 2012 google acquired hassabis deep mind when it was clear his training of mnachine learning ihn gmes lile go was going to achieve leaps like open sourcing 250 million plroteins. Thhis work continuens mainly out of cambridge and london offiecs whilst demi is als key to google own leaps into ai. One partnership google deep mind, nvidia, and disney todays owners of pixar is newton robotics. Codibg pixels with pixar when owned by steve jobs circa 2002 was arguably where nvidia first saw ai as the nain ourpose of the company. Today nvidia not ponly codes pixels but increasingly beleives ai will soon blurv line between programmking and simply defining what problem you want help withy in normal human convrerssation
Yann Lecun is the most connected academic in ai and what were once the famous 3 of algorith wplrd (ie Hinton and bengio). Hinton has retired; bengio and lecun do summer camps. But lecun who first proved ai can do zipcodes in early 90s connects his chair pout of nyu courant maths lab wityh meta models from west coast to east coast tro france and india - egde o[pen ai models like llama and mistral are While the sacling iof llama by meta and mistral by mistral - the valiadtion as open academic models came from Lecun. The timing was good as the ai world series summit started by king charles has through France Macron and Modi india ended the drag onAI caused by EU bureaucracy.
Country sponsor -if you speak english then King Charles support of AI as the most important innovation was timely; french modi; india - we are talking about ai agenting youth brains and productivie life not just big corporate ai nor gov ai by a few superpowers
Jun 25
chris macrae
Deep%20Compute%20Resources%20Comparison.docx
Axios AI+
Apologies for missing that yesterday was National Typewriter Day, an embarrassing oversight for someone who has three actual and two Lego typewriters. Today's AI+ is 1,090 words, a 4-minute read.
Illustration: Aïda Amer/Axios
Elon Musk still isn't happy with how his AI platform answers divisive questions, pledging in recent days to retrain Grok so it will answer in ways more to his liking.
Why it matters: Efforts to steer AI in particular directions could exacerbate the danger of a technology already known for its convincing but inaccurate hallucinations.
The big picture: Expect more of Musk's thumb-on-the-scale approach, as governments and businesses build and embrace AI models with preferred responses on hot-button topics from LGBTQ rights to territorial disputes.
Driving the news: In a series of tweets over the past week, Musk has expressed frustration at the ways Grok was answering questions and suggested an extensive effort to manipulate its output.
Reality check: AI models are already hallucinating in ways that suggest failed attempts by company staff to manipulate outputs.
Between the lines: These early stumbles highlight the challenges of tweaking large language models, but researchers say there are more sophisticated ways to inject preferences that could be both more pervasive and harder to detect.
What they're saying: AI ethicists say the problem extends well beyond Musk and Grok. Many companies have been exploring how they can tweak answers to appeal to users, regulators and other constituencies.
Yes, but: Efforts to scour all bias from generative AI are doomed because the human data AI trains on is full of bias.
Bottom line: Ultimately — as we reported over a year ago — it boils down to a battle over what values powerful AI systems will hold.
Jun 26